NICE recommends endobronchial valve insertion to reduce lung volume in emphysema

The UK National Institute for Health and Care Excellence (NICE) issued updated guidance saying that current evidence is sufficient to support the routine use of endobronchial valve insertion to reduce lung volume in the treatment of emphysema. Pulmonx CEO Glen French remarked that the move "will increase patient access to our proven and minimally-invasive Zephyr technology, which has the potential to significantly improve the quality of life for patients."

According to Pulmonx, the guidance update was based on safety and efficacy data from multiple clinical studies evaluating its Zephyr endobronchial valves. The company said results from the BeLieVeR-HiFITRANSFORM, STELVIO and IMPACT trials showed that the devices were able "to significantly improve lung function, exercise tolerance and quality of life in emphysema patients with no collateral ventilation, as assessed with the Chartis System."

Pulmonx noted that its minimally-invasive, one-way valves are placed via a flexible bronchoscope in airways in the lungs to occlude diseased regions and reduce lung hyperinflation, allowing the healthier lung regions to function more efficiently. The company added that Zephyr endobronchial valves are routinely used in Europe and Australia as a treatment for severe emphysema.

Did you like this article?